Navigation Links
CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
Date:1/15/2010

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious diseases, announced today the appointment of Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility.  Mr. Burkhart has over 30 years of experience in the manufacture and process development of biologicals, medical devices and other Active Pharmaceutical Ingredients (APIs).  During his distinguished  career in the Pharmaceutical and Biopharmaceutical Industry and prior to joining CEL-SCI, Mr. Burkhart has been responsible for all aspects of GMP manufacturing and operations, including production, materials controls and facilities maintenance.  In addition he has extensive experience in the design of manufacturing facilities meeting FDA GMP requirements.  Mr. Burkhart has also been involved in the building and/or running a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics.

Geert Kersten, Chief Executive Officer of CEL-SCI, said:  "We are pleased to have been able to attract to our team such an accomplished executive, with deep experience and expertise in all facets of the manufacturing process for biologics and other drugs. This hire represents another step CEL-SCI has taken in order to increase the likelihood of a successful outcome of its global pivotal Phase III study of Multikine® for the treatment of head and neck cancer."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global pivotal Phase III clinical trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S. technology platform.  This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This unique investigational treatment is currently being tested in a clinical study at The Johns Hopkins University Hospital.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
2. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
5. CEL-SCI Expands H1N1 Flu Virus Work
6. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
7. CEL-SCI Posts New Corporate Presentation to Website
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... --  The Harrington Discovery Institute at University ... has announced the 2017 recipients of Harrington Scholar-Innovator ... whose research shows promise to advance the standard ... – part of The Harrington Project for Discovery ... medicine: to advance early breakthroughs into the clinical ...
(Date:1/16/2017)... Jan. 16, 2017 When synthetic Fentanyl arrived on ... product as top-rate. They offered free samples, inviting would-be customers ... Soon, business was booming. ... 100 times more powerful than morphine, has racked up a ... last 2 years. One dealer,s recorded fentanyl sales reveals that ...
(Date:1/16/2017)... According to the new market research report "Display Controller Market by Type ... Controller), Application (Industrial Control, Medical Equipment, Automotive, Mobile Communication), and Geography - ... grow from USD 17.26 Billion in 2015 to reach USD 32.24 Billion ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
(Date:1/15/2017)... ... 2017 , ... "On Tour is a music themed slideshow production package which ... Austin - CEO of Pixel Film Studios. , On Tour’s new slide presets ... animation of their slideshows. Place each slide on top of another slide or piece ...
(Date:1/15/2017)... ... January 15, 2017 , ... The ... is pleased to announce that it will be assisting HackensackUMC Mountainside with its ... Glen Ridge townships, servicing all surrounding towns. The firm will be working closely ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze ... transition from one clip to the next. , To use “Cut-Out First” presets, ...
(Date:1/13/2017)... ... January 13, 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of ... generation companion scanner and data collector at the National Retail Federation’s Big Show (NRF17) ... an answer to the market’s need for more compact and rugged devices for collecting ...
Breaking Medicine News(10 mins):